GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

NCT02333110 · tracked via the Priya Life Science Canada tracker

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Phase

Not applicable

Started

2015-01

Last updated

2026-05-12

Condition(s) studied

Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation

Investigational drug(s) / intervention(s)

spatially fractionated radiation therapy

spatially fractionated radiation therapy: A single dose of 15-20Gys of spatially fractionated radiation therapy

Study summary

Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible. * Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation * Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis * WHO performance status of 0-2 * Aged 18 years or older * Ability to sign and understand an informed consent form Exclusion Criteria: * Potentially curable patient * Previous palliative radiation with hypofractionation * Tumor located near the spinal cord or in the brain * Pregnant or nursing woman

Primary outcome measure(s)

Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire — 3 months post treatment

Trial sites (1)

Facility	City	Region	Status
Sir Mortimer Jewish General Hospital	Montreal	Quebec	Recruiting

More Sir Mortimer B. Davis - Jewish General Hospital trials in Canada

Hypotension Prediction Index in Postoperative Surgical Patients Recruiting

Aggressive Smoking Cessation Trial (ASAP) Recruiting

Montreal Immune-Related Adverse Events (MIRAE) Study Recruiting

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery Recruiting

Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02333110 on ClinicalTrials.gov ↗ ← All trials in Canada